Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Receptos

- PMLiVE

AZ’s MYSTIC survival data is in – and it’s a bust

Imfinzi failed to achieve OS improvement

- PMLiVE

AZ says target of $45bn sales by 2023 still achievable

Q3 revenues topped analyst expectations

- PMLiVE

AZ and Clovis PARP inhibitors show their mettle at ESMO

Lynparza and Rubraca both on track to extend cancer patient reach

- PMLiVE

AZ and Medicines Catapult collaborate on innovative sound tech in drug discovery

Collaborates with Medicines Discovery Catapult on AMI-MS

- PMLiVE

China: AstraZeneca’s new engine for growth and innovation

AstraZeneca’s Mark Mallon talks to PME about how its long-term investment in China is paying off

- PMLiVE

FDA rejects GSK’s Nucala for COPD

Says evidence that Nucala was effective in preventing COPD exacerbations was insufficient

AstraZeneca AZ

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

Clinical data from the TSLP targeting antibody is due in 2020

AstraZeneca AZ

AstraZeneca’s Lupus treatment misses mark in trial

Anifrolumab failed to show statistically significant reduction in disease activity

AstraZeneca AZ

AZ rival to GSK’s COPD drug Anoro fails head-to-head test

Its combo missed two of the main endpoints of the study

AstraZeneca AZ

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

Japanese regulator clears the drug for first-line use in NSCLC

AstraZeneca AZ

New cancer drugs can’t quite plug the revenue hole at AZ

Overall sales fell 5% to $10.33bn

- PMLiVE

AZ’s Lynparza closes in on first line ovarian cancer use

Aims for first-line indication in the ovarian cancer setting

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links